<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gynecomastia in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gynecomastia in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gynecomastia in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sharonda A Taylor, MD, FAAP, FSAHM, Dipl. of ABOM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elise DeVore Berlan, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell E Geffner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 10, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2465915627">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic will focus on the evaluation of gynecomastia in children and adolescents. Gynecomastia in adults is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">
          "Clinical features, diagnosis, and evaluation of gynecomastia in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">
          "Management of gynecomastia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27397518">
         <span class="h1">
          DEFINITION AND CHARACTERISTIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gynecomastia is the benign proliferation of glandular breast tissue in males. It differs from proliferation of breast tissue in females in that there is no terminal alveolar development in response to progesterone [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Gynecomastia is characterized by a mass or ridge of glandular tissue that is symmetrically distributed around the areolar-nipple complex  (
         <a class="graphic graphic_figure graphicRef72334" href="/z/d/graphic/72334.html" rel="external">
          figure 1
         </a>
         ). It can generally be detected when the glandular tissue is &gt;0.5 cm (0.2 inches) in diameter. Gynecomastia may be tender to palpation early in the course. It is usually bilateral, but some patients present with unilateral enlargement or bilateral enlargement with one side larger than the other or enlarging weeks to months before the other [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p>
         The distinct mass of glandular tissue, central location, and symmetrical shape distinguish gynecomastia from other causes of male breast enlargement in children and adolescents [
         <a href="#rid1">
          1,5,6
         </a>
         ]. (See
         <a class="local">
          'Mimics of gynecomastia'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3474393109">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children and adolescents, gynecomastia is common during the neonatal period and during puberty  (
         <a class="graphic graphic_figure graphicRef64368" href="/z/d/graphic/64368.html" rel="external">
          figure 2
         </a>
         ). Gynecomastia is uncommon in prepubertal males. The epidemiology of gynecomastia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27397525">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gynecomastia is presumed to be caused by a relative imbalance between androgens (testosterone and androstenedione) and estrogens (estradiol and
         <a class="drug drug_general" data-topicid="107870" href="/z/d/drug information/107870.html" rel="external">
          estrone
         </a>
         ). The hormonal imbalance may be caused by an absolute increase in free estrogens, decrease in endogenous free androgens, a relative increase in the free estrogen-to-free androgen ratio, androgen insensitivity, or estrogen-like drug effects  (
         <a class="graphic graphic_table graphicRef53166" href="/z/d/graphic/53166.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         Transient neonatal gynecomastia is thought to result from placental transformation of dehydroepiandrosterone and dehydroepiandrosterone sulfate (derived from the fetus and mother) to
         <a class="drug drug_general" data-topicid="107870" href="/z/d/drug information/107870.html" rel="external">
          estrone
         </a>
         and estradiol, which enter the fetal circulation and stimulate glandular proliferation in the breast. (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2284.html" rel="external">
          "Placental development and physiology", section on 'Steroid hormones'
         </a>
         .)
        </p>
        <p>
         The pathophysiology of pubertal gynecomastia is likely related to the transient estrogen/androgen imbalance caused by the earlier rise of serum estradiol than serum androgen concentrations to adult levels. However, most observational studies have not found differences in single point measurements of estradiol in males with and without pubertal gynecomastia [
         <a href="#rid7">
          7-10
         </a>
         ]. In observational studies, males with gynecomastia have greater expression of aromatase in skin fibroblasts and higher concentrations of insulin-like growth factor-1 (IGF-1) than males without gynecomastia [
         <a href="#rid10">
          10,11
         </a>
         ]. Aromatase locally converts androgen to estrogen, and IGF-1 is necessary for breast proliferation [
         <a href="#rid10">
          10,11
         </a>
         ]. Additional studies suggest that changes in sex hormone-binding globulin levels (due to medications and illnesses such as liver disease) may impact estradiol levels [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Pubertal gynecomastia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27397539">
         <span class="h1">
          CAUSES OF GYNECOMASTIA
         </span>
        </p>
        <p class="headingAnchor" id="H1949033283">
         <span class="h2">
          Physiologic gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of cases of gynecomastia in children and adolescents are physiologic  (
         <a class="graphic graphic_table graphicRef109486" href="/z/d/graphic/109486.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2955817177">
         <span class="h3">
          Neonatal breast hypertrophy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal breast hypertrophy (which occurs in both males and females) is presumably related to placental transformation of androgens to estrogens, which enter the fetal circulation and stimulate glandular proliferation  (
         <a class="graphic graphic_picture graphicRef110966" href="/z/d/graphic/110966.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2284.html" rel="external">
          "Placental development and physiology", section on 'Steroid hormones'
         </a>
         .)
        </p>
        <p>
         Neonatal breast hypertrophy usually regresses spontaneously and completely within the first year of life. Approximately 5 percent of cases may be associated with galactorrhea [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/104.html" rel="external">
          "Breast masses in children and adolescents", section on 'Neonates and infants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2088189159">
         <span class="h3">
          Pubertal gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pubertal gynecomastia is a physiologic enlargement of the glandular breast tissue that occurs in some males during puberty. In most studies, it occurs in &gt;50 percent of male adolescents (range 4 to 69 percent) [
         <a href="#rid1">
          1,3,12,14-16
         </a>
         ]. The wide range is related to differences in study population, diagnostic criteria, and observer technique [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The prevalence of pubertal gynecomastia peaks during mid-puberty, coinciding with peak height velocity at age 12 to 14 years, pubic hair sexual maturity rating (Tanner stage) 3 to 4  (
         <a class="graphic graphic_picture graphicRef80005" href="/z/d/graphic/80005.html" rel="external">
          picture 2
         </a>
         ), and testicular volumes of 8 to 10 mL bilaterally  (
         <a class="graphic graphic_figure graphicRef60225" href="/z/d/graphic/60225.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid3">
          3,5,10,14,15,17-19
         </a>
         ]. It is usually bilateral (64 percent of cases in the largest cross-sectional study) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Adolescents with pubertal gynecomastia usually complain of a mass or lump behind the nipple [
         <a href="#rid5">
          5
         </a>
         ]. The enlargement occurs gradually and should not exceed 4 cm (1.6 inches) in diameter. Palpable fibroglandular enlargement ≥4 cm (1.6 inches) in diameter or rapidly progressive glandular enlargement may be associated with an underlying disorder [
         <a href="#rid5">
          5,20,21
         </a>
         ]. (See
         <a class="local">
          'Pathologic gynecomastia'
         </a>
         below.)
        </p>
        <p>
         The breast may be tender for approximately six months after onset, but tenderness gradually resolves as the glandular tissue undergoes fibrosis and the inflammatory reaction and stretching of tissues diminish [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         When left untreated, pubertal gynecomastia regresses substantially or resolves in &gt;70 percent of patients after one year [
         <a href="#rid2">
          2,14,15
         </a>
         ], although it may take up to three years for some patients [
         <a href="#rid18">
          18,19
         </a>
         ]. Gynecomastia that persists for ≥1 year or after age 17 years is less likely to spontaneously regress [
         <a href="#rid14">
          14,15,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H898568116">
         <span class="h2">
          Pathologic gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathologic gynecomastia is rare in children and adolescents but may be associated with substantial morbidity (eg, testicular, adrenal, or pituitary tumors)  (
         <a class="graphic graphic_table graphicRef109486" href="/z/d/graphic/109486.html" rel="external">
          table 2
         </a>
         ). Pathologic gynecomastia usually is associated with other abnormalities on physical examination or clinical features that are not characteristic of physiologic gynecomastia, such as [
         <a href="#rid5">
          5,6,20,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occurrence outside the neonatal or pubertal age group
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occurrence in prepubertal males who have no other secondary sexual characteristics (eg, testicular enlargement, pubic hair or axillary hair, axillary odor)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid progression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enlargement &gt;4 cm (1.6 inches) in diameter [
         <a href="#rid20">
          20
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistence for more than one year or after age 17 years; persistent pubertal gynecomastia accounts for a large proportion of gynecomastia in young adults [
         <a href="#rid6">
          6
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Pathologic gynecomastia has a number of causes including:
        </p>
        <p class="headingAnchor" id="H3600581233">
         <span class="h3">
          Drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The proportion of cases of gynecomastia in children and adolescents that are related to drugs is unknown. A variety of prescription, over-the-counter, and illicit drugs may be associated with gynecomastia  (
         <a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">
          table 3
         </a>
         ), but the association is not necessarily causal [
         <a href="#rid1">
          1,15,24-27
         </a>
         ].
        </p>
        <p>
         Children and adolescents may be exposed to the following drugs/substances that have been associated with gynecomastia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Estrogens or substances that act like estrogens in medications (eg, oral contraceptive pills, digitalis) and cosmetics (lotions, lavender oil, and tea tree oil) [
         <a href="#rid28">
          28-30
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/113968.html" rel="external">
          "Endocrine-disrupting chemicals"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that enhance endogenous estrogen production (eg, gonadotropins,
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that inhibit testosterone synthesis and/or action (eg,
         <a class="drug drug_pediatric" data-topicid="13401" href="/z/d/drug information/13401.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          cimetidine
         </a>
         ); the effect is related to dose and duration of use
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiretroviral therapy for human immunodeficiency virus (HIV) (see
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs with other mechanisms (eg, hyperprolactinemia) of gynecomastia:
         <a class="drug drug_pediatric" data-topicid="13393" href="/z/d/drug information/13393.html" rel="external">
          isoniazid
         </a>
         , calcium channel blockers, ACE inhibitors, amphetamines,
         <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13347" href="/z/d/drug information/13347.html" rel="external">
          haloperidol
         </a>
         , antipsychotics (especially
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         ), proton pump inhibitors, and tricyclic antidepressants [
         <a href="#rid26">
          26,31,32
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol and recreational or illicit drugs, including [
         <a href="#rid1">
          1,20
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Marijuana, particularly if used ≥4 times per week [
         <a href="#rid33">
          33-35
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anabolic steroids (see
         <a class="medical medical_review" href="/z/d/html/7475.html" rel="external">
          "Use of androgens and other hormones by athletes", section on 'Gynecomastia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4136658668">
         <span class="h3">
          Hypogonadism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary (hypergonadotropic) hypogonadism accounts for approximately 8 percent and secondary (hypogonadotropic) hypogonadism accounts for approximately 2 percent of cases of gynecomastia in adult patients seeking consultation for gynecomastia [
         <a href="#rid1">
          1
         </a>
         ]. It is not known how frequently hypogonadism causes gynecomastia in children and adolescents.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Klinefelter syndrome, polysomy X
         </strong>
         , is the most common congenital cause of primary hypogonadism and often presents during adolescence. As many as 70 percent of patients with Klinefelter syndrome have gynecomastia (often bilateral), which usually is slowly progressive [
         <a href="#rid5">
          5,36
         </a>
         ]. Although gynecomastia is common among patients with Klinefelter syndrome, in a small study, the incidence of gynecomastia in adolescents with Klinefelter syndrome was similar to that in chromosomally typical males [
         <a href="#rid36">
          36
         </a>
         ]. Rapidly progressive gynecomastia in patients with Klinefelter syndrome may indicate an extragonadal human chorionic gonadotropin (hCG)-secreting tumor in the mediastinum; these malignant germ cell tumors occur in approximately 1 percent of patients with Klinefelter syndrome [
         <a href="#rid37">
          37,38
         </a>
         ]. Other clinical features of Klinefelter syndrome include tall, thin body habitus; long arms and legs; learning, language, or behavioral difficulties; and small (&lt;3 cm [1.2 inches] in length or 5 mL in volume), firm testes in pubertal-aged males. Patients with Klinefelter syndrome have an increased risk of breast cancer [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">
          "Causes of primary hypogonadism in males", section on 'Klinefelter syndrome'
         </a>
         and
         <a class="local">
          'Tumors'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/779.html" rel="external">
          "Breast cancer in men", section on 'Alterations of the estrogen to androgen ratio'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other congenital causes
         </strong>
         of primary hypogonadism that may be associated with gynecomastia include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cryptorchidism, including anorchia (testicular regression) (see
         <a class="medical medical_review" href="/z/d/html/2850.html" rel="external">
          "Undescended testes (cryptorchidism) in children: Clinical features and evaluation"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Enzyme defects of testosterone production (see
         <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">
          "Causes of primary hypogonadism in males", section on 'Disorders of androgen biosynthesis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other genetic conditions, syndromes, or polymorphisms (examples can be found in the Online Mendelian Inheritance in Man [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2F&amp;token=87jLzclRwWxNoI%2BQq5Gg719fkmhU1%2BHL5BgfqtERBlQ%3D&amp;TOPIC_ID=14310" target="_blank">
          OMIM
         </a>
         ] database by searching on "
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fomim%2F%3Fterm%3Dgynecomastia&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F1mEzbrra1EyPWuMKBWRSz3dLNWp5BVQbr25TQL5Fg2lh2rYLrToFvdBLHnwc3uV7w%3D%3D&amp;TOPIC_ID=14310" target="_blank">
          gynecomastia
         </a>
         ")
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired causes
         </strong>
         of primary hypogonadism in children and adolescents include infections that affect the testes (mumps, echovirus, group B arboviruses, leprosy), trauma (eg, testicular torsion), and radiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary hypogonadism
         </strong>
         may be congenital (eg, congenital gonadotropin-releasing hormone deficiency) or acquired (eg, pituitary tumor [
         <a href="#rid40">
          40
         </a>
         ], hyperprolactinemia). (See
         <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">
          "Causes of secondary hypogonadism in males"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1447883677">
         <span class="h3">
          Tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of tumors may cause gynecomastia by presumably altering the balance of androgens and estrogens. (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Causes of gynecomastia'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testicular tumors
         </strong>
         (Leydig or Sertoli cell tumors, germ cell tumors) occur predominantly in young men (15 to 35 years). The reported incidence of testicular tumors in men with gynecomastia is 3 percent [
         <a href="#rid1">
          1,41
         </a>
         ]; gynecomastia may be the only clinical finding at the time of diagnosis [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A testicular mass may be palpable on examination. (See
         <a class="medical medical_review" href="/z/d/html/2980.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of testicular cancer is increased in patients with a history of cryptorchidism. (See
         <a class="medical medical_review" href="/z/d/html/87856.html" rel="external">
          "Undescended testes (cryptorchidism) in children: Management", section on 'Testicular cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of Sertoli cell tumors is increased in patients with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F175200&amp;token=87jLzclRwWxNoI%2BQq5Gg710FisxCOcFWEhyuUsi3YR3MgSZX1Fn0ISugtD98cooM&amp;TOPIC_ID=14310" target="_blank">
          Peutz-Jeghers syndrome
         </a>
         , an autosomal dominant condition characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation  (
         <a class="graphic graphic_picture graphicRef80815 graphicRef112236 graphicRef89492" href="/z/d/graphic/80815.html" rel="external">
          picture 3A-C
         </a>
         ), and increased risk of gastrointestinal and nongastrointestinal cancer. (See
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Testicular tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Feminizing adrenal tumors
         </strong>
         typically are aggressive and malignant; males with feminizing adrenal tumors may have testicular atrophy and decreased libido in addition to gynecomastia. (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Other rare causes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/137.html" rel="external">
          "Clinical presentation and evaluation of adrenocortical tumors", section on 'Androgen and estrogen-secreting tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          hCG-producing tumors
         </strong>
         may arise in the testes (germ-cell tumors), lungs, mediastinum, liver, kidneys, or brain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H906649976">
         <span class="h3">
          Other pathologic causes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic liver or kidney diseases
         </strong>
         – Chronic liver or kidney diseases may be associated with gynecomastia [
         <a href="#rid16">
          16
         </a>
         ]. Chronic liver disease affects sex hormone binding globulin levels, which alter the circulating levels of estradiol and testosterone. Kidney disease alters testosterone production from Leydig cells. There is also an increase in estradiol and luteinizing hormone. In addition, the effects of chronic disease on the hypothalamic-pituitary-testicular (HPT) axis, medications used in disease management, and declining nutrition contribute to the development of gynecomastia [
         <a href="#rid44">
          44
         </a>
         ]. It is estimated that chronic disease accounts for approximately 8 percent of cases of gynecomastia in adult patients seeking consultation for gynecomastia [
         <a href="#rid1">
          1
         </a>
         ]. It is not known how frequently chronic disease causes gynecomastia in children and adolescents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malnutrition
         </strong>
         – Malnutrition suppresses the HPT axis leading to decreased testosterone production. However, during refeeding, the HPT axis re-engages. This increases production of testosterone and estradiol similar to that seen during physiologic puberty. (See
         <a class="local">
          'Pubertal gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperthyroidism
         </strong>
         – Hyperthyroidism is an uncommon cause of gynecomastia, estimated to cause approximately 1.5 percent of cases in adult patients evaluated for gynecomastia [
         <a href="#rid1">
          1
         </a>
         ]; it is not known how frequently hyperthyroidism causes gynecomastia in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other features of hyperthyroidism in children and adolescents include goiter, accelerated growth, ophthalmopathy (exophthalmos, stare, and lid lag), tachycardia, increased appetite without weight gain (or with weight loss), and tremor. However, gynecomastia may be the first manifestation of hyperthyroidism [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5841.html" rel="external">
          "Clinical manifestations and diagnosis of Graves disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aromatase excess syndrome
         </strong>
         –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F139300&amp;token=87jLzclRwWxNoI%2BQq5Gg723w07gAAlBS2CREYu1Snn3hnqtG6urPMdAa6FvUwuo9&amp;TOPIC_ID=14310" target="_blank">
          Aromatase excess syndrome
         </a>
         (also called familial prepubertal gynecomastia) is a heterogeneous autosomal dominant disorder characterized by accelerated early linear growth with low or normal final height, advanced bone age, prepubertal gynecomastia, and testicular failure [
         <a href="#rid5">
          5,46
         </a>
         ]. It is caused by a gain-of-function mutation in the
         <em>
          CYP19
         </em>
         (aromatase) gene [
         <a href="#rid47">
          47-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial androgen insensitivity syndrome
         </strong>
         –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F312300&amp;token=87jLzclRwWxNoI%2BQq5Gg71wq4hgWwJUm7Ae%2F2FQC9aMCgbRWFhw0w5wq7JmeB6XI&amp;TOPIC_ID=14310" target="_blank">
          Partial androgen insensitivity syndrome
         </a>
         (PAIS) is an X-linked disorder caused by mutations in the androgen receptor (
         <em>
          AR
         </em>
         ) gene that is associated with gynecomastia, decreased virilization, and a small phallus in males. In a retrospective case series, 14 of 14 male patients with PAIS developed gynecomastia at puberty [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">
          "Pathogenesis and clinical features of disorders of androgen action", section on 'Partial androgen insensitivity (PAIS)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Partial androgen insensitivity occurs in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F313200&amp;token=87jLzclRwWxNoI%2BQq5Gg791C2PMY8GEJRr9ePhNcve%2BPRob3gbdKo6N1THWxtH2a&amp;TOPIC_ID=14310" target="_blank">
          X-linked spinal and bulbar muscular atrophy
         </a>
         (also known as Kennedy disease), which may present with gynecomastia in adolescence or before puberty [
         <a href="#rid52">
          52-54
         </a>
         ]. Associated clinical features may include muscle fasciculations, weakness, muscle cramps, and calf hypertrophy. (See
         <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">
          "Pathogenesis and clinical features of disorders of androgen action", section on 'Spinobulbar muscular atrophy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital adrenal hyperplasia
         </strong>
         – Various forms of congenital adrenal hyperplasia, including 11-beta-hydroxylase deficiency [
         <a href="#rid55">
          55,56
         </a>
         ],
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F201810&amp;token=87jLzclRwWxNoI%2BQq5Gg72AM0i7MEGwhUW1tfjX%2B8T32qQvLew7lQZ1zmfMMcnss&amp;TOPIC_ID=14310" target="_blank">
          3-beta hydroxysteroid dehydrogenase deficiency
         </a>
         [
         <a href="#rid57">
          57
         </a>
         ], and late-onset 21-hydroxylase deficiency [
         <a href="#rid58">
          58
         </a>
         ], on rare occasion, present with gynecomastia due to increased production of estrogen precursors [
         <a href="#rid59">
          59-61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">
          "Uncommon congenital adrenal hyperplasias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/144.html" rel="external">
          "Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ovotesticular differences of sex development
         </strong>
         – Ovotesticular differences of sex development (previously called "true hermaphroditism") are characterized by the presence of both ovarian follicular and testicular tubular tissue in the same individual. Associated clinical features may include hypospadias and cryptorchidism [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/118045.html" rel="external">
          "Causes of differences of sex development", section on 'Gonadal overproduction of androgens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2611920575">
         <span class="h1">
          MIMICS OF GYNECOMASTIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mimics of gynecomastia in infants include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mastitis
         </strong>
         – In infants younger than two months, unilateral or bilateral breast enlargement may be caused by mastitis (cellulitis or abscess of the breast). Associated clinical features include swelling, erythema, warmth, tenderness, and induration of the breast with or without purulent nipple discharge. Gynecomastia is not warm, indurated, or associated with purulent nipple discharge. (See
         <a class="medical medical_review" href="/z/d/html/5974.html" rel="external">
          "Mastitis and breast abscess in infants younger than two months", section on 'Introduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Galactocele
         </strong>
         – Galactocele (a benign milk-filled cystic lesion, which may be associated with milky nipple discharge) is a rare cause of unilateral or bilateral breast enlargement in infants [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Mimics of gynecomastia in children and adolescents include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pseudogynecomastia
         </strong>
         – Pseudogynecomastia is fatty infiltration of the breast (also called lipomastia). It is a common finding, especially in adolescents who are overweight (body mass index [BMI] ≥85
         <sup>
          th
         </sup>
         and &lt;95
         <sup>
          th
         </sup>
         percentile for age) or obese (BMI ≥95
         <sup>
          th
         </sup>
         percentile for age). The lack of a discrete mass or ridge of glandular tissue distinguishes pseudogynecomastia from gynecomastia  (
         <a class="graphic graphic_figure graphicRef72334" href="/z/d/graphic/72334.html" rel="external">
          figure 1
         </a>
         ). On palpation, pseudogynecomastia feels similar to adjacent adipose tissue in the anterior axillary fold [
         <a href="#rid37">
          37
         </a>
         ]. In pubertal males, transition from gynecomastia to lipomastia is common [
         <a href="#rid50">
          50,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breast carcinoma
         </strong>
         <strong>
          and other tumors
         </strong>
         – Breast carcinoma is extremely rare in male children and adolescents [
         <a href="#rid66">
          66,67
         </a>
         ]; &lt;1 percent of breast cancer occurs in males, with a median age of 67 years [
         <a href="#rid68">
          68,69
         </a>
         ]. Risk factors for breast cancer in males include Klinefelter syndrome, gonadal failure, obesity, radiation exposure, and positive family history of
         <em>
          BRCA2
         </em>
         gene mutations [
         <a href="#rid70">
          70,71
         </a>
         ]. Other primary or metastatic tumors may present with breast masses including rhabdomyosarcoma, angiosarcoma, lymphoma, leukemia, and neuroblastoma [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In contrast to gynecomastia, breast carcinoma and other tumors usually are eccentrically located and fixed to the chest wall  (
         <a class="graphic graphic_figure graphicRef72334" href="/z/d/graphic/72334.html" rel="external">
          figure 1
         </a>
         ). Breast carcinoma may be associated with skin dimpling, nipple retraction, and nipple bleeding, or discharge [
         <a href="#rid73">
          73
         </a>
         ], none of which is typical of gynecomastia. Breast carcinoma usually is not associated with tenderness, which may occur in the early development of gynecomastia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other breast masses
         </strong>
         – Other masses that may occur in the male breast include lipomas, hemangiomas, hematomas, neurofibromas, lymphangiomas, and dermoid cysts [
         <a href="#rid16">
          16,74
         </a>
         ]. Unlike gynecomastia, these often are unilateral and tend to be eccentrically located.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27397604">
         <span class="h1">
          APPROACH TO DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The history and examination of children and adolescents with gynecomastia focus on clinical features of pathologic causes of gynecomastia  (
         <a class="graphic graphic_table graphicRef109486" href="/z/d/graphic/109486.html" rel="external">
          table 2
         </a>
         ). Laboratory and imaging studies usually are not necessary in adolescents with clinical features typical of physiologic gynecomastia.
        </p>
        <p class="headingAnchor" id="H3303874209">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important aspects of the history in children and adolescents with gynecomastia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breast enlargement
         </strong>
         – The size, timing of onset, and duration of breast enlargement: Breast size ≥4 cm and rapid progression may indicate greater hormone imbalance and a pathologic cause [
         <a href="#rid5">
          5
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pubertal status and age
         </strong>
         – Beyond the neonatal period, prepubertal gynecomastia is always pathologic; pubertal gynecomastia is most common during mid-puberty (eg, age 12 to 14 years, during peak height velocity, or at sexual maturity rating [Tanner stage] 3 to 4  (
         <a class="graphic graphic_figure graphicRef60225" href="/z/d/graphic/60225.html" rel="external">
          figure 3
         </a>
         )) [
         <a href="#rid5">
          5,10,17-19
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Associated symptoms
         </strong>
         – Mild pain is normal during the early development of physiologic gynecomastia, and may also occur with mastitis, but is unusual in breast carcinoma; galactorrhea may indicate hyperprolactinemia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Review of systems
         </strong>
         – Symptoms of a previously undiagnosed endocrine abnormality or chronic illness, particularly [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypogonadism – Atypical genitalia, undervirilization
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperthyroidism – Goiter, tachycardia, tremor, increased appetite without weight gain, accelerated linear growth
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aromatase excess syndrome – Early accelerated linear growth
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liver disease – Anorexia, nausea, vomiting, acholic stools, edema, jaundice, spider angiomata
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Renal disease – Anorexia, nausea, vomiting, edema, changes in urination, hematuria
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Human chorionic gonadotropin (hCG)-producing tumor – Rapid and significant virilization with only slightly enlarged testes, headache
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolactinoma – Headache, galactorrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Family history
         </strong>
         – Family history of gynecomastia or hypogonadism  (
         <a class="graphic graphic_table graphicRef109487" href="/z/d/graphic/109487.html" rel="external">
          table 4
         </a>
         ), testicular cancer, and liver or kidney disease (see
         <a class="local">
          'Pathologic gynecomastia'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications/drugs
         </strong>
         – Exposure to medications, including over-the-counter drugs, marijuana, dietary supplements, and herbal products that are associated with gynecomastia  (
         <a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="local">
          'Drugs'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial effects
         </strong>
         – The degree to which gynecomastia affects school or social life (may have bearing on management and follow-up) (see
         <a class="local">
          'Management'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27397618">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important aspects of the physical examination of children and adolescents with gynecomastia include:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breast
         </strong>
         – Proper examination of the breast differentiates gynecomastia from pseudogynecomastia (lipomastia) and other causes of breast enlargement. The patient is examined in the supine position with their hands beneath their head  (
         <a class="graphic graphic_figure graphicRef72334" href="/z/d/graphic/72334.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Galactorrhea may indicate hyperprolactinemia. Overlying skin changes (skin dimpling), nipple bleeding or discharge, or axillary adenopathy may be associated with breast carcinoma (extremely rare in children and adolescents).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genitalia
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sexual maturity rating
         </strong>
         – Physiologic gynecomastia typically occurs at pubic hair sexual maturity rating (Tanner stage) 3 to 4  (
         <a class="graphic graphic_picture graphicRef80005" href="/z/d/graphic/80005.html" rel="external">
          picture 2
         </a>
         ); pathologic causes of gynecomastia should be considered if the sexual maturity rating is stage 1 or 5.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Testes
         </strong>
         – Physiologic gynecomastia typically occurs at testicular volumes of 8 to 10 mL bilaterally  (
         <a class="graphic graphic_figure graphicRef60225" href="/z/d/graphic/60225.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Testes that are small (&lt;2.5 cm [1 inch] in length or &lt;5 mL in volume  (
         <a class="graphic graphic_picture graphicRef117431" href="/z/d/graphic/117431.html" rel="external">
          picture 4
         </a>
         )), atrophied, or absent suggest that the patient is prepubertal or has hypogonadism, and additional evaluation is warranted. Small, firm testes may suggest Klinefelter syndrome. A testicular mass may indicate testicular cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Scrotum and phallus
         </strong>
         – A bifid scrotum and/or hypospadias may indicate partial androgen insensitivity or other causes of congenital hypogonadism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other aspects of the physical examination
         </strong>
         – Other aspects of the physical examination may suggest a pathologic cause or mimic of gynecomastia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Body mass index
         </strong>
         – Body mass index (BMI) ≥85
         <sup>
          th
         </sup>
         percentile may indicate pseudogynecomastia rather than gynecomastia, although it does not definitively exclude gynecomastia [
         <a href="#rid4">
          4
         </a>
         ]; weight loss (or lack of gain) may indicate hyperthyroidism or malignancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Height
         </strong>
         – Early accelerated linear growth in prepubertal males may suggest aromatase excess syndrome or hyperthyroidism; tall stature with long extremities may suggest Klinefelter syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thyroid
         </strong>
         – Palpable goiter suggests hyperthyroidism; other signs of hyperthyroidism include ophthalmopathy (exophthalmos, stare, and lid lag), tachycardia, and tremor.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Abdomen
         </strong>
         – An abdominal mass may indicate an adrenal tumor or extragonadal germ cell tumor. Hepatomegaly may indicate a hCG-secreting tumor or chronic liver disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Virilization
         </strong>
         – Undervirilization may indicate hypogonadism, partial androgen insensitivity, congenital adrenal hyperplasia (3-beta hydroxysteroid dehydrogenase deficiency), or an ovotesticular difference of sex development. Rapid or precocious virilization may indicate an hCG-secreting tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Skin
         </strong>
         – Perioral pigmentation (ie, dark blue to dark brown macules around the mouth or on the buccal mucosa  (
         <a class="graphic graphic_picture graphicRef80815 graphicRef112236" href="/z/d/graphic/80815.html" rel="external">
          picture 3A-B
         </a>
         )) may indicate
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F175200&amp;token=87jLzclRwWxNoI%2BQq5Gg710FisxCOcFWEhyuUsi3YR3MgSZX1Fn0ISugtD98cooM&amp;TOPIC_ID=14310" target="_blank">
          Peutz-Jeghers syndrome
         </a>
         , which is associated with an increased risk of Sertoli cell tumors. (See
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Extra-intestinal cancers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Genital tract cancers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Jaundice and spider angiomata may indicate liver disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Edema may indicate renal disease. (See
         <a class="medical medical_review" href="/z/d/html/6134.html" rel="external">
          "Chronic kidney disease in children: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Musculoskeletal
         </strong>
         – Muscle fasciculations, weakness, and calf hypertrophy may indicate
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F313200&amp;token=87jLzclRwWxNoI%2BQq5Gg791C2PMY8GEJRr9ePhNcve%2BPRob3gbdKo6N1THWxtH2a&amp;TOPIC_ID=14310" target="_blank">
          X-linked spinal and bulbar muscular atrophy
         </a>
         , which is associated with partial androgen insensitivity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3373408146">
         <span class="h2">
          Initial laboratory evaluation and management
         </span>
        </p>
        <p class="headingAnchor" id="H2860460272">
         <span class="h3">
          Drug or medication exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient has been exposed to a drug (eg, marijuana), medication, or herbal therapy that is known to be associated with gynecomastia  (
         <a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">
          table 3
         </a>
         ), the agent should be discontinued. Improvement (decreased tenderness and softening of the glandular tissue) within one month of discontinuation supports the agent as the cause [
         <a href="#rid6">
          6
         </a>
         ]. However, drug-induced gynecomastia of &gt;12 months' duration is unlikely to regress because of fibrosis.
        </p>
        <p class="headingAnchor" id="H375599708">
         <span class="h3">
          Other cause suggested by history or examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Targeted laboratory and imaging studies should be performed if the initial evaluation suggests an underlying cause other than drug/medication exposure  (
         <a class="graphic graphic_table graphicRef109490" href="/z/d/graphic/109490.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H459917317">
         <span class="h3">
          Prepubertal gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gynecomastia in prepubertal males without any other secondary sexual characteristics (eg, increased testicular volume, pubic hair) is usually pathologic and should prompt a search for an underlying etiology [
         <a href="#rid75">
          75
         </a>
         ]. If the initial evaluation and/or the targeted evaluation do not suggest a cause, we suggest obtaining an early morning blood sample to measure serum hCG, estradiol, testosterone, luteinizing hormone (LH), and dehydroepiandrosterone sulfate (DHEAS) [
         <a href="#rid5">
          5
         </a>
         ]. An early morning sample is recommended because serum testosterone concentration varies during the day and is highest in the morning. Referral to a pediatric endocrinologist is recommended [
         <a href="#rid5">
          5,16
         </a>
         ]. Although a specific cause is rarely identified [
         <a href="#rid76">
          76
         </a>
         ], evaluation is necessary because of the potential morbidity associated with the various causes. (See
         <a class="local">
          'Indications for referral'
         </a>
         below and
         <a class="local">
          'Pathologic gynecomastia'
         </a>
         above.)
        </p>
        <p>
         The interpretation of initial laboratory studies is discussed below. (See
         <a class="local">
          'Laboratory interpretation and additional evaluation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1000549306">
         <span class="h3">
          Pubertal gynecomastia
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Typical pubertal gynecomastia
         </strong>
         – Laboratory studies generally are not necessary for adolescents with clinical features typical of pubertal gynecomastia [
         <a href="#rid1">
          1,16,19,37,77
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tender gynecomastia with onset at mid-puberty (ie, age 12 to 14 years, pubic hair sexual maturity rating [Tanner stage] 3 or 4, testicular volume 8 to 10 mL)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History and physical examination not suggestive of a pathologic cause
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of physiologic pubertal gynecomastia typically entails reassurance and observation. The majority of cases resolve spontaneously within one to three years of onset [
         <a href="#rid14">
          14,15,18,19
         </a>
         ]. (See
         <a class="local">
          'Physiologic gynecomastia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pubertal gynecomastia with atypical features
         </strong>
         – Clinical features that are not typical of physiologic pubertal gynecomastia include rapid progression, diameter ≥4 cm (1.6 inches), rapid and/or precocious virilization, and persistence for ≥24 months or after age 17 years [
         <a href="#rid18">
          18,78
         </a>
         ]. Consensus regarding the laboratory evaluation of adolescents with asymptomatic, atypical pubertal gynecomastia is lacking [
         <a href="#rid18">
          18,79
         </a>
         ]. Our evaluation typically includes early morning measurement of serum hCG, estradiol, testosterone, LH, and DHEAS [
         <a href="#rid1">
          1,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The interpretation of initial laboratory studies is discussed below. (See
         <a class="local">
          'Laboratory interpretation and additional evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3493652121">
         <span class="h2">
          Laboratory interpretation and additional evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of the laboratory tests direct additional laboratory or imaging studies  (
         <a class="graphic graphic_table graphicRef109488" href="/z/d/graphic/109488.html" rel="external">
          table 6
         </a>
         ). Laboratory results must be interpreted in the context of age and pubertal status (eg, low testosterone is normal for a prepubertal male but abnormal for a pubertal-aged adolescent).
        </p>
        <p class="headingAnchor" id="H1457069806">
         <span class="h3">
          Increased hCG
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated hCG (regardless of the other results) suggests an hCG-secreting tumor (testicular germ cell, extragonadal germ cell tumor, or hCG-secreting nontrophoblastic tumor).
        </p>
        <p>
         Additional evaluation typically includes testicular ultrasonography for testicular mass.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A testicular mass in a patient with elevated hCG suggests a testicular germ cell tumor. Referral to a pediatric urologist or oncologist is warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of a testicular mass, imaging of the chest and abdomen (and possibly other sites [eg, brain]) is warranted to look for an extragonadal germ cell tumor or hCG-secreting nontrophoblastic tumor. If found in the anterior mediastinum, a karyotype is mandatory to assess for Klinefelter syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">
          "Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5199.html" rel="external">
          "Intracranial germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3354365763">
         <span class="h3">
          Increased estradiol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated estradiol in a child or adolescent with gynecomastia may indicate a Leydig or Sertoli cell testicular tumor, feminizing adrenal tumor, increased extraglandular aromatase activity, congenital adrenal hyperplasia, or ovotesticular differences of sex development  (
         <a class="graphic graphic_table graphicRef109488" href="/z/d/graphic/109488.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef109752" href="/z/d/graphic/109752.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H748701560">
         <span class="h3">
          Increased testosterone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased testosterone and increased LH may indicate androgen resistance or hyperthyroidism  (
         <a class="graphic graphic_table graphicRef109488" href="/z/d/graphic/109488.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef109751" href="/z/d/graphic/109751.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
         Additional evaluation includes thyroid function tests (free thyroxine, total tri-iodothyronine, and thyroid-stimulating hormone [TSH]):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased free thyroxine and/or tri-iodothyronine and decreased TSH indicate hyperthyroidism. (See
         <a class="medical medical_review" href="/z/d/html/5841.html" rel="external">
          "Clinical manifestations and diagnosis of Graves disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Androgen resistance (eg, partial androgen insensitivity) should be considered if free thyroxine, total tri-iodothyronine, and TSH are normal. (See
         <a class="medical medical_review" href="/z/d/html/7471.html" rel="external">
          "Diagnosis and treatment of disorders of the androgen receptor"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1365258198">
         <span class="h3">
          Decreased testosterone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decreased testosterone in a pubertal-aged male may indicate primary or secondary hypogonadism or hyperprolactinemia  (
         <a class="graphic graphic_table graphicRef109488" href="/z/d/graphic/109488.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef109751" href="/z/d/graphic/109751.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased testosterone with increased LH indicates primary hypogonadism. (See
         <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">
          "Causes of primary hypogonadism in males"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">
          "Clinical features and diagnosis of male hypogonadism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased testosterone with normal or decreased LH may indicate secondary hypogonadism or hyperprolactinemia, possibly due to a prolactin-secreting pituitary tumor (even in the absence of galactorrhea).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional evaluation includes measurement of serum prolactin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevated prolactin (hyperprolactinemia) may indicate the presence of a prolactin-secreting pituitary tumor; additional evaluation may include magnetic resonance imaging of the head. (See
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia", section on 'Laboratory/imaging tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Normal prolactin suggests other causes of secondary hypogonadism. (See
         <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">
          "Causes of secondary hypogonadism in males"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27397639">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of gynecomastia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">
          "Management of gynecomastia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3151231524">
         <span class="h2">
          Physiologic gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the majority of cases of physiologic pubertal gynecomastia resolve spontaneously within a year of onset, management decisions are individualized according to the degree of psychosocial distress.
        </p>
        <p>
         Given the usual natural history, many patients can be managed with reassurance and observation. Adjunctive psychotherapy may be beneficial for adolescents with psychosocial consequences of gynecomastia (eg, bullying and decreased self-esteem) [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         The frequency of follow-up varies with the degree of psychosocial distress and the clinical setting. Primary care providers may monitor pubertal gynecomastia every three to six months (often in conjunction with follow-up of other adolescent health issues), particularly if gynecomastia affects the patient's school or social life [
         <a href="#rid1">
          1,6,16,23
         </a>
         ]. Less frequent follow-up, or no follow-up, may be appropriate for patients who are not bothered by gynecomastia provided that the gynecomastia regresses as expected over the next 12 months. Although referral to a pediatric endocrinologist for patients with typical pubertal gynecomastia is not necessary, patients whose diagnosis of pubertal gynecomastia has been confirmed by a pediatric endocrinologist should follow up as recommended by the specialist.
        </p>
        <p>
         We do not routinely suggest pharmacologic therapy for pubertal gynecomastia in adolescents. Evidence supporting the efficacy of pharmacologic therapy for pubertal gynecomastia in adolescents is limited to case reports and uncontrolled studies [
         <a href="#rid5">
          5,80
         </a>
         ], and the US Food and Drug Administration (FDA) has not approved any drug for this indication. Nonetheless, pharmacologic therapy may be warranted for select patients (eg, those with physiologic gynecomastia that is &gt;4 cm [1.6 inches] in diameter [which is unlikely to spontaneously regress], rapidly progressive, or associated with embarrassment that interferes with normal daily activities). Pharmacologic therapy is most effective during the proliferative phase of breast development, which lasts approximately 12 months. Pharmacologic therapy for gynecomastia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">
          "Management of gynecomastia", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
         Surgical therapy may be warranted for adolescents with physiologic gynecomastia that is &gt;3 cm (1.2 inches) in diameter, unresponsive to medical therapy, persists for more than two years or after age 16 years, or is associated with embarrassment that interferes with normal daily activities [
         <a href="#rid18">
          18,77,81,82
         </a>
         ]. Before surgery is performed, biochemical evaluation (early morning human chorionic gonadotropin [hCG], estradiol, testosterone, luteinizing hormone [LH], dehydroepiandrosterone sulfate [DHEAS]) may be warranted (if not already performed) to avoid delaying diagnosis of a pathologic condition that has clinical implications (eg, requires specific directed treatment, affects fertility) [
         <a href="#rid16">
          16
         </a>
         ]. When surgery is performed in adolescents, we suggest that tissue be sent for histology, given rare reports of incidental breast carcinoma [
         <a href="#rid5">
          5,83
         </a>
         ]. Surgical management of gynecomastia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">
          "Management of gynecomastia", section on 'Surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3694402562">
         <span class="h2">
          Pathologic gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of pathologic gynecomastia depends upon the underlying cause. In general, gynecomastia resolves with discontinuation of the offending medication/environmental exposure or treatment of the underlying condition. These measures should be undertaken before pharmacologic or surgical therapy, which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">
          "Management of gynecomastia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1953438813">
         <span class="h1">
          INDICATIONS FOR REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for referral in children or adolescents with gynecomastia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prepubertal gynecomastia – Refer to a pediatric endocrinologist to evaluate for an endogenous or exogenous source of estrogen and other endocrine abnormalities [
         <a href="#rid5">
          5,16,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast enlargement that is not gynecomastia – Referral to a pediatric surgeon may be warranted for children and adolescents with breast enlargement that is not characteristic of gynecomastia (eg, eccentric enlargement, fixed mass, etc) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endocrine abnormality (primary or secondary hypogonadism, hyperthyroidism, androgen resistance, increased extraglandular aromatase activity) – Refer to a pediatric endocrinologist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testicular mass on testicular ultrasonography – Refer to a pediatric urologist/oncologist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other tumor (adrenal, extragonadal germ cell, pituitary) suspected on imaging – Refer to a pediatric oncologist.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10404544">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16107.html" rel="external">
          "Patient education: Gynecomastia (male breast development) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2186.html" rel="external">
          "Patient education: Gynecomastia (breast enlargement in males) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27397681">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Gynecomastia is the benign proliferation of glandular breast tissue in males and is characterized by a mass or ridge of glandular tissue that is symmetrically distributed around the areolar-nipple complex  (
         <a class="graphic graphic_figure graphicRef72334" href="/z/d/graphic/72334.html" rel="external">
          figure 1
         </a>
         ). These features distinguish gynecomastia from other causes of male breast enlargement in children and adolescents. (See
         <a class="local">
          'Definition and characteristic features'
         </a>
         above and
         <a class="local">
          'Mimics of gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and pathophysiology
         </strong>
         – In the pediatric age range, gynecomastia is common in the neonatal period and during puberty. (See
         <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">
          "Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gynecomastia is thought to be caused by a relative imbalance between androgens (testosterone and androstenedione) and estrogens (estradiol and
         <a class="drug drug_general" data-topicid="107870" href="/z/d/drug information/107870.html" rel="external">
          estrone
         </a>
         )  (
         <a class="graphic graphic_table graphicRef53166" href="/z/d/graphic/53166.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physiologic gynecomastia
         </strong>
         – Physiologic pubertal gynecomastia typically occurs during mid-puberty. Adolescents complain of a mass or lump behind the nipple. The breast may be tender for approximately six months after onset. Pubertal gynecomastia regresses spontaneously in the majority of adolescents but is unlikely to regress if it persists for ≥1 year or after age 17 years. (See
         <a class="local">
          'Pubertal gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic gynecomastia
         </strong>
         – Clinical features suggestive of pathologic gynecomastia include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Occurrence outside the neonatal or pubertal age range
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Occurrence in prepubertal males
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid progression
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Enlargement &gt;4 cm (1.6 inches) in diameter
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid and/or precocious virilization
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pathologic causes of gynecomastia include drugs/medications  (
         <a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">
          table 3
         </a>
         ), hypogonadism, tumors, and endocrinologic abnormalities  (
         <a class="graphic graphic_table graphicRef109486" href="/z/d/graphic/109486.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Causes of gynecomastia'
         </a>
         above and
         <a class="local">
          'Pathologic gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to diagnosis
         </strong>
         – The history and examination of children and adolescents with gynecomastia focuses on the clinical features of pathologic causes of gynecomastia, including drugs/medications; age and pubertal status; family history; associated symptoms; growth parameters; palpation of the breasts; and evaluation of the testicles for size, masses, and consistency  (
         <a class="graphic graphic_table graphicRef109486" href="/z/d/graphic/109486.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'History'
         </a>
         above and
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The initial laboratory evaluation and management depend on whether a cause is suggested by the history and examination:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If the patient has been exposed to a medication or herbal therapy associated with gynecomastia  (
         <a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">
          table 3
         </a>
         ), the agent should be discontinued. Clinical improvement within one month of discontinuation supports the agent as the cause. (See
         <a class="local">
          'Drug or medication exposure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If the history and examination suggest a cause other than drug/medication exposure, targeted laboratory and imaging studies should be performed  (
         <a class="graphic graphic_table graphicRef109490" href="/z/d/graphic/109490.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Other cause suggested by history or examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In prepubertal males, if the history and examination do not suggest a cause, we suggest obtaining an early morning blood sample to measure serum human chorionic gonadotropin (hCG), estradiol, testosterone, luteinizing hormone (LH), and dehydroepiandrosterone sulfate (DHEAS). (See
         <a class="local">
          'Prepubertal gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In adolescents with clinical features of typical pubertal gynecomastia, laboratory studies generally are not necessary. Initial management usually consists of reassurance and observation. (See
         <a class="local">
          'Pubertal gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Clinical features that are not typical of physiologic pubertal gynecomastia include rapid progression, diameter ≥4 cm (1.6 inches), and persistence for ≥12 months or after age 17 years. Our evaluation for such patients consists of early morning measurement of serum hCG, estradiol, testosterone, LH, and DHEAS. (See
         <a class="local">
          'Pubertal gynecomastia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The results of the initial laboratory tests direct additional laboratory and imaging studies  (
         <a class="graphic graphic_table graphicRef109488" href="/z/d/graphic/109488.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef109752" href="/z/d/graphic/109752.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef109751" href="/z/d/graphic/109751.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Laboratory interpretation and additional evaluation'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li RZ, Xia Z, Lin HH, et al. Childhood gynecomastia: a clinical analysis of 240 cases. Zhongguo Dang Dai Er Ke Za Zhi 2007; 9:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumanov P, Deepinder F, Robeva R, et al. Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 2007; 41:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen H, Webb ML, DiVasta AD, et al. Adolescent gynecomastia: not only an obesity issue. Ann Plast Surg 2010; 64:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma NS, Geffner ME. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975; 86:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr 1979; 95:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mieritz MG, Sorensen K, Aksglaede L, et al. Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia. Clin Endocrinol (Oxf) 2014; 80:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mieritz MG, Rakêt LL, Hagen CP, et al. A Longitudinal Study of Growth, Sex Steroids, and IGF-1 in Boys With Physiological Gynecomastia. J Clin Endocrinol Metab 2015; 100:3752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984; 58:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc 2009; 84:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madlon-Kay DJ. 'Witch's milk'. Galactorrhea in the newborn. Am J Dis Child 1986; 140:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NYDICK M, BUSTOS J, DALE JH Jr, RAWSON RW. Gynecomastia in adolescent boys. JAMA 1961; 178:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990; 116:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordt CA, DiVasta AD. Gynecomastia in adolescents. Curr Opin Pediatr 2008; 20:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limony Y, Friger M, Hochberg Z. Pubertal gynecomastia coincides with peak height velocity. J Clin Res Pediatr Endocrinol 2013; 5:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra AK, Amed S, Bucevska M, et al. Do Adolescents with Gynecomastia Require Routine Evaluation by Endocrinology? Plast Reconstr Surg 2018; 142:9e.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soliman AT, De Sanctis V, Yassin M. Management of Adolescent Gynecomastia: An Update. Acta Biomed 2017; 88:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahoney CP. Adolescent gynecomastia. Differential diagnosis and management. Pediatr Clin North Am 1990; 37:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sher ES, Migeon CJ, Berkovitz GD. Evaluation of boys with marked breast development at puberty. Clin Pediatr (Phila) 1998; 37:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marynick SP, Nisula BC, Pita JC Jr, Loriaux DL. Persistent pubertal macromastia. J Clin Endocrinol Metab 1980; 50:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson G. Gynecomastia. Am Fam Physician 2012; 85:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999; 6:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol 2015; 71:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eugene AR, Eugene B. An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers. F1000Res 2018; 7:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trinchieri A, Perletti G, Magri V, et al. Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. Arch Ital Urol Androl 2021; 93:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottswinter JM, Korth-Schütz S, Ziegler R. Gynecomastia caused by estrogen containing hair lotion. J Endocrinol Invest 1984; 7:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiRaimondo CV, Roach AC, Meador CK. Gynecomastia from exposure to vaginal estrogen cream. N Engl J Med 1980; 302:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashfaq M, Haroon MZ, Alkahraman YM. Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders. Endocr Regul 2022; 56:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon SWY, Siu KK, Tsang AMC. Isoniazid-induced gynaecomastia: report of a paediatric case and review of literature. BMC Endocr Disord 2020; 20:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med 1974; 290:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmon J, Aliapoulios MA. Gynecomastia in marihuana users. N Engl J Med 1972; 287:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmon JW, Aliapoulios MA. Marijuana-induced gynecomastia: clinical and laboratory experience. Surg Forum 1974; 25:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler G. Incidence of gynaecomastia in Klinefelter syndrome adolescents and outcome of testosterone treatment. Eur J Pediatr 2021; 180:3201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 2014; 10:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. Br J Cancer 1995; 71:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swerdlow AJ, Schoemaker MJ, Higgins CD, et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005; 97:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald SM, Rapalino O, Sherry NA, et al. Case 32-2016. A 20-Year-Old Man with Gynecomastia. N Engl J Med 2016; 375:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels IR, Layer GT. Testicular tumours presenting as gynaecomastia. Eur J Surg Oncol 2003; 29:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolitsas N, Tsambalas S, Dimitriadis F, et al. Gynecomastia as a first clinical sign of nonseminomatous germ cell tumor. Urol Int 2011; 87:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris M, Rizvi S, Hindmarsh J, Bryan R. Testicular tumour presenting as gynaecomastia. BMJ 2006; 332:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuhaci N, Polat SB, Evranos B, et al. Gynecomastia: Clinical evaluation and management. Indian J Endocrinol Metab 2014; 18:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon DL, Brown JL, Emanuele NV, Hall L 3rd. Gynecomastia as the initial manifestation of hyperthyroidism. Endocr Pract 1997; 3:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binder G, Iliev DI, Dufke A, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005; 90:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukami M, Miyado M, Nagasaki K, et al. Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia. Pediatr Endocrinol Rev 2014; 11:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukami M, Tsuchiya T, Vollbach H, et al. Genomic basis of aromatase excess syndrome: recombination- and replication-mediated rearrangements leading to CYP19A1 overexpression. J Clin Endocrinol Metab 2013; 98:E2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukami M, Ogata T. Congenital disorders of estrogen biosynthesis and action. Best Pract Res Clin Endocrinol Metab 2022; 36:101580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellmann P, Christiansen P, Johannsen TH, et al. Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Arch Dis Child 2012; 97:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouwsma G, Van Wijngaarden GK. Spinal muscular atrophy and hypertrophy of the calves. J Neurol Sci 1980; 44:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sperfeld AD, Karitzky J, Brummer D, et al. X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 2002; 59:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echaniz-Laguna A, Rousso E, Anheim M, et al. A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy. Neurology 2005; 64:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasniewska M, Arrigo T, Lombardo F, et al. 11-Hydroxylase deficiency as a cause of pre-pubertal gynecomastia. J Endocrinol Invest 2009; 32:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zadik Z, Pertzelan A, Kaufman H, et al. Gynaecomastia in two prepubertal boys with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. Helv Paediatr Acta 1979; 34:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavanah SF, Dons RF. Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male. Metabolism 1993; 42:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasniewska M, Raiola G, Galati MC, et al. Non-classical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia. Eur J Pediatr 2008; 167:1083.
          </a>
         </li>
         <li class="breakAll">
          Levine LS, DiGeorge AM. Adrenal disorders and genital abnormalities. In: Nelson Textbook of Pediatrics, 16th ed, Behman RE, Kliegman RM, Jenson HB (Eds), WB Saunders, Philadelphia 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auchterlonie IA, Cameron J, Wallace AM, et al. Pre-pubertal gynaecomastia as the presenting feature of late-onset 21-hydroxylase deficiency. Horm Res 1985; 22:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackett MD PR, Freeman MD DA. Androstenedione aromatization as a cause of gynecomastia in 11beta-hydroxylase and 21-hydroxylase deficiencies. Endocr Pract 1996; 2:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khadilkar KS, Budyal SR, Kasaliwal R, et al. OVOTESTICULAR DISORDER OF SEX DEVELOPMENT: A SINGLE-CENTER EXPERIENCE. Endocr Pract 2015; 21:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman J, Messazos B, Sharples-Blissland N, Cameron F. Extreme physiological gynaecomastia in the neonate: Observation not intervention. J Paediatr Child Health 2015; 51:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajdev SK, Makwana N, Lester R, Agwu JC. An unusual case of bilateral galactocoele in a male infant. Arch Dis Child 2011; 96:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinehr T, Kulle A, Barth A, et al. Transition from gynaecomastia to lipomastia in pubertal boys. Clin Endocrinol (Oxf) 2021; 94:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; 367:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Sagar P, Friedmann AM, et al. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 12-2016. An 8-Year-Old Boy with an Enlarging Mass in the Right Breast. N Engl J Med 2016; 374:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005; 10:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010; 28:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst 2014; 106:djt465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García CJ, Espinoza A, Dinamarca V, et al. Breast US in children and adolescents. Radiographics 2000; 20:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellegrin MC, Naviglio S, Cattaruzzi E, et al. A Teenager with Sudden Unilateral Breast Enlargement. J Pediatr 2017; 182:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang M, Lee CJ, Hwang IT, et al. Prepubertal unilateral gynecomastia in the absence of endocrine abnormalities. Ann Pediatr Endocrinol Metab 2014; 19:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einav-Bachar R, Phillip M, Aurbach-Klipper Y, Lazar L. Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol (Oxf) 2004; 61:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemaine V, Cayci C, Simmons PS, Petty P. Gynecomastia in adolescent males. Semin Plast Surg 2013; 27:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ersek RA, Schaeferele M, Beckham PH, Salisbury MA. Gynecomastia: A clinical review. Aesthet Surg J 2000; 20:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowers SP, Pearlman NW, McIntyre RC Jr, et al. Cost-effective management of gynecomastia. Am J Surg 1998; 176:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapid O, van Wingerden JJ, Perlemuter L. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review. J Pediatr Endocrinol Metab 2013; 26:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abaci A, Buyukgebiz A. Gynecomastia: review. Pediatr Endocrinol Rev 2007; 5:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuzzi LC, Firriolo JM, Pike CM, et al. The Effect of Surgical Treatment for Gynecomastia on Quality of Life in Adolescents. J Adolesc Health 2018; 63:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handschin AE, Bietry D, Hüsler R, et al. Surgical management of gynecomastia--a 10-year analysis. World J Surg 2008; 32:38.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14310 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8421478" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17937844" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Childhood gynecomastia: a clinical analysis of 240 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17659215" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20395797" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Adolescent gynecomastia: not only an obesity issue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18622206" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Gynecomastia in prepubertal and pubertal men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17881754" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical practice. Gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1111683" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The relationship of concentrations of serum hormones to pubertal gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/448573" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24033660" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26287961" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A Longitudinal Study of Growth, Sex Steroids, and IGF-1 in Boys With Physiological Gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6693546" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19880691" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Gynecomastia: pathophysiology, evaluation, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3946357" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : 'Witch's milk'. Galactorrhea in the newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14480779" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Gynecomastia in adolescent boys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2137877" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hormonal studies and physical maturation in adolescent gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18622190" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Gynecomastia in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24072080" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pubertal gynecomastia coincides with peak height velocity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29952889" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Do Adolescents with Gynecomastia Require Routine Evaluation by Endocrinology?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28845839" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of Adolescent Gynecomastia: An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2259545" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adolescent gynecomastia. Differential diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9637901" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation of boys with marked breast development at puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7188613" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Persistent pubertal macromastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22534349" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10731125" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Aromatase and gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25827472" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Gynecomastia and drugs: a critical evaluation of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30271581" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34933535" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267908" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prepubertal gynecomastia linked to lavender and tea tree oils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6438223" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Gynecomastia caused by estrogen containing hair lotion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7366629" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gynecomastia from exposure to vaginal estrogen cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35489049" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33109161" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Isoniazid-induced gynaecomastia: report of a paediatric case and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4816961" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Depression of plasma testosterone levels after chronic intensive marihuana use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5075561" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Gynecomastia in marihuana users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4439214" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Marijuana-induced gynecomastia: clinical and laboratory experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33934233" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Incidence of gynaecomastia in Klinefelter syndrome adolescents and outcome of testosterone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25112235" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Gynaecomastia--pathophysiology, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7841064" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cancer incidence in men with Klinefelter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16106025" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27797319" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Case 32-2016. A 20-Year-Old Man with Gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12798747" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Testicular tumours presenting as gynaecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21625076" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Gynecomastia as a first clinical sign of nonseminomatous germ cell tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16601045" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Testicular tumour presenting as gynaecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24741509" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gynecomastia: Clinical evaluation and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251481" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Gynecomastia as the initial manifestation of hyperthyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15483104" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12736278" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24716396" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24064691" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Genomic basis of aromatase excess syndrome: recombination- and replication-mediated rearrangements leading to CYP19A1 overexpression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34538723" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Congenital disorders of estrogen biosynthesis and action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22412043" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7354373" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Spinal muscular atrophy and hypertrophy of the calves.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12470181" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : X-linked bulbospinal neuronopathy: Kennedy disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15851746" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636210" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : 11-Hydroxylase deficiency as a cause of pre-pubertal gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/457432" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Gynaecomastia in two prepubertal boys with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8446050" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17992539" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Non-classical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17992539" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Non-classical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2411646" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pre-pubertal gynaecomastia as the presenting feature of late-onset 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251547" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Androstenedione aromatization as a cause of gynecomastia in 11beta-hydroxylase and 21-hydroxylase deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25786559" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : OVOTESTICULAR DISORDER OF SEX DEVELOPMENT: A SINGLE-CENTER EXPERIENCE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25940908" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Extreme physiological gynaecomastia in the neonate: Observation not intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21849296" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : An unusual case of bilateral galactocoele in a male infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33351202" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Transition from gynaecomastia to lipomastia in pubertal boys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16488803" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Male breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27096583" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 12-2016. An 8-Year-Old Boy with an Enlarging Mass in the Right Breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079314" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A review of the diagnosis and management of male breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996029" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Male breast cancer: a population-based comparison with female breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24552677" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15668471" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Epidemiology of male breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112814" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Breast US in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12379069" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Breast cancer in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27956018" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A Teenager with Sudden Unilateral Breast Enlargement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25346921" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prepubertal unilateral gynecomastia in the absence of endocrine abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15212645" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Prepubertal gynaecomastia: aetiology, course and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24872741" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Gynecomastia in adolescent males.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Gynecomastia: A clinical review
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9926805" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cost-effective management of gynecomastia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23729603" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17925790" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Gynecomastia: review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30279103" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The Effect of Surgical Treatment for Gynecomastia on Quality of Life in Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18026791" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Surgical management of gynecomastia--a 10-year analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
